Global Pricing and Reimbursement Strategies are quickly becoming a key role in the Bio-Pharmaceutical and Medical Device industries. With a number of countries looking for ways to save money, more and more are cutting healthcare costs by reducing the price paid for drugs, reducing the number of devices they are reimbursing and establishing innovative value-based schemes to ensure their money is paying for their perceived best drugs. Being able to utilize clinical, regional and therapeutic data to show value for your product is becoming key when seeking entry into these groups. In addition, the passing of the Affordable Care Act on March 23, 2010, has led to many questions for domestic private and governmental payers. This conference will look at Health Technology Assessment in emerging and established markets.
The conference will look at creating value-based dossiers in establishing comparative effectiveness models as well as working with payers, domestic and international, to create Conditional-Based agreements to ensure formulary inclusion. Utilizing comparative effectiveness has become increasingly important in describing the value of your product. At the same time, U.S. international payers are using these models to determine inclusion and price of drugs and devices.
By attending this conference, you will learn how to access and locate data, as well as properly establish and analyze metrics, models and methods. You will walk away with invaluable knowledge on what data and analysis payers look in order to include your drug on their formulary lists, (within health technology assessment) and learn effective ways of communicating your value proposition.
For additional information visit the conference website at http://www.marcusevansch.com/biofchc270 or email firstname.lastname@example.org.